Welcome to the 4th TCR-based Therapies for Solid Tumors Summit

The first TCR-based therapy approval in the US and Europe at the start of last year sparked a rush of excitement, investment and collaborations. As further developers move into the clinic and some near commercialization, it’s time for this community to unite to address the critical bottlenecks faced in development, from discovery to approval, to guarantee smooth sailing through the clinic.

The 4^th TCR-based Therapies for Solid Tumors Summit returned to Boston as the must-attend forum for TCR experts to come together to share industry updates and next generation engineered approaches to boost therapy safety and efficacy.

Leaders and newcomers including Immunocore, Medigene, Immatics, Captain T Cell and Anocca collaborated to guarantee tumor-specificity, prevent cross-reactivity, boost TCR and target discovery, enhance solid tumor durability and explore TCR modalities.

Huge milestones were achieved for the TCR field in 2022, however, there’s no time to sit back and relax. Collaborate with like-minded TCR trailblazers in 2024 to secure clinical validation and streamline the road from discovery to commercialization.